Poster AbstractsProteomics Core Facility. The data is processed and students examinetheir results and use bioinformatics tools to further understand thebiological implications <strong>of</strong> the results. The students than present theirfindings, describe specific proteins that showed differential expression.A hypothesis is presented explaining the biological relevance <strong>of</strong> theprotein expression change along with a plan for testing this hypothesis.This work was sponsored by Grant Number P20 RR16462, from theIDeA Networks <strong>of</strong> Biomedical Research Excellence (INBRE) <strong>Program</strong> <strong>of</strong>the National Center for Research Resources (NCRR), a component <strong>of</strong>the National Institutes <strong>of</strong> Health (NIH).186 Quantitative Western Blotting withAmersham ECL PrimeM. Winkvist, S. Grimsby, K. Söderquist,A. MarcussonGE Healthcare Bio-Sciences AB, Uppsala, SwedenWestern blotting is a well established technique used to study proteinsfrom a wide variety <strong>of</strong> sources. The technique is used throughout thelife sciences from basic research to medical diagnostic applications.Western Blot is at best considered as semi-quantitative and hencelimited to studies involving large protein differences.Here wedemonstrate the use <strong>of</strong> a new ECL TM reagent, Amersham TM ECL Primein a number <strong>of</strong> typical Western Blotting applications. The resultsdemonstrate that, Amersham ECL Prime can be used for detection <strong>of</strong>low abundant proteins, that signals are very stable over time and covera broad dynamic range. These features make Amersham ECL Primehighly suitable for accurate quantitative analysis.187 New Approaches to QuantitativeWestern BlottingM. Winkvist, Å. Hagner-McWhirter,K. Söderquist, S. GrimsbyGE Healthcare Bio-Sciences AB, Uppsala, SwedenFluorescent detection in Western blotting <strong>of</strong>fers high sensitivity, broaddynamic range and stability <strong>of</strong> signals. This makes it highly suitable forquantitative Western blotting. Here we show how fluorescent Westernblotting can be used for simultaneously detection <strong>of</strong> up to threedifferent proteins on the same blot at the same time and for detection<strong>of</strong> proteins <strong>of</strong> the same molecular weight without stripping and reprobing.We also demonstrate how fluorescent Western blotting with3 layer probing can be used to increase sensitivity and thereby enablesdetection <strong>of</strong> very low abundant proteins. Finally we demonstrate thatit is possible to compare the total protein amount to the target proteinby using Deep Purple TM protein staining prior to ECLTM Plex TM Westernblotting.188 Rubicon PicoPlex-NGS Kits Availablefor Sequencing Single Cells Using theIllumina Genome AnalyzerJ. Langmore, T. Kurihara, E. Kamberov,J. M’Mwirichia, T. Tesmer, D. OldfieldRubicon Genomics, Ann Arbor, MI, United StatesRubicon Genomics has released its PicoPlex-NGS kits to prepare singlecells for NGS analysis on the Illumina Genome Analyzer. These kitsenable single eukaryotic or prokaryotic cells to be lysed, DNA extractedand amplified, and adapted for paired-end sequencing in a 1-tube,3-hr, 4-step process. Although the read coverage is poor in a single lane,the reproducibility <strong>of</strong> the reads allows single cells to be compared forSNP and CNV genotype, mutations. The same amplified samples canbe used for PCR and microarray analysis, including genome-wide SNPgenotyping, mutation, and copy number analysis. PRC amplification ortarget enrichment can be used for high accuracy and coverage singlecellgenomic analysis.189 PRG-<strong>2011</strong>: Defining the InteractionBetween Users and Suppliers <strong>of</strong>Proteomics Services/FacilitiesD.H. Hawke 1 , T.M. Andacht 2 , M.K. Bunger 3 ,C.E. Bystrom 4 , L.J. Dangott 5 , H. Molina 6 ,R.L. Moritz 7 , R.E. Settlage 8 , C.W. Turck 91University <strong>of</strong> Texas MD Anderson Cancer Center,Houston, TX, United States; 2 Centers for DiseaseControl and Prevention, Atlanta, GA, UnitedStates; 3 RTI International, Research TrianglePark, NC, United States; 4 Quest Diagnostics, SanJuan Capistrano, CA, United States; 5 Texas A&MUniversity, College Station, TX, United States;6Center for Genome Regulation, Barcelona,Spain; 7 Institute for Systems Biology, Seattle, WA,United States; 8 Virginia Bioinformatics Institute,Blacksburg, VA, United States; 9 Max Planck Institute<strong>of</strong> Psychiatry, Munich, GermanyOver the last ten years the Proteomics Research Group (PRG) hasundertaken technical studies that have covered a wide range <strong>of</strong> issuesunique to the rapidly developing field <strong>of</strong> proteomics. These studieshaveincluded a range <strong>of</strong> qualitative and quantitative experiments. The PRGstudies have resulted in a great deal <strong>of</strong> attention not only within the<strong>ABRF</strong> community but also outside as is evident from numerous articlesdealing with proteomics methods, procedures and standardization.As the field continues to develop, the diversity <strong>of</strong> instrumentationand laboratory workflows have grown in tandem. Therefore, for thePRG<strong>2011</strong> study it seemed especially useful to perform a survey tohelp define future studies based on the current blend <strong>of</strong> sample typesand technologies and obtain a view <strong>of</strong> emerging trends. A survey wascreated to ascertain three main insights into core facility function: 1)How labs interact with their clients, 2) The capacity <strong>of</strong> labs to meet thedemands <strong>of</strong> their clients, and 3) The blend <strong>of</strong> experimental techniques<strong>of</strong>fered to and requested by clients. Survey questions were designed toobtain information from both users <strong>of</strong> core facilities and the directorsand personnel <strong>of</strong> core facilities. Questions covered such topics as thetype and age <strong>of</strong> instruments in use, how data is analyzed and presentedto client, sources <strong>of</strong> funding, and emerging proteomics trends. Resultsare compiled en masse and presented without regard to institution.190 GlycoMaster — S<strong>of</strong>tware forGlycopeptide Identification withCombined ETD and CID/HCD SpectraP. Shan, L. XinBioinformatics Solutions Inc., Waterloo, ON,CanadaObjective: To automate the data analysis for the identification <strong>of</strong>glycopeptides with combined ETD and CID/HCD fragmentation. Theinputs for GlycoMaster s<strong>of</strong>tware include the raw mass spectrometry84 • <strong>ABRF</strong> <strong>2011</strong> — Technologies to Enable Personalized Medicine
data <strong>of</strong> a Thermo Orbitrap instrument and the list <strong>of</strong> proteins inthe sample. The list <strong>of</strong> proteins can be identified from the samemass spectrometry data by using a database search method. Thes<strong>of</strong>tware uses the signature ions <strong>of</strong> simple sugars in the HCD spectrato identify the HCD-ETD spectrum pairs <strong>of</strong> glycopeptides. Thenthe ETD spectrum in each pair is used to identify the glycopeptidesequence, the glycosylation site and glycan mass. The output <strong>of</strong>the s<strong>of</strong>tware is an excel file that contains information about theidentified glycopeptides, including glycan composition, mass error,glycan components, glycosylation site and glycopeptide sequence.A score is associated with each identification result that can be usedto sort the identifications according to confidence. GlycoMaster wastested with an ETD-CID dataset containing 3561 MS and 2738 MS/MS spectra from tryptic digest <strong>of</strong> reduced and alkylated 12 standardprotein mixture containing 3 glycoproteins ( human serotransferrin,chicken ovalabumin and ovomucoid) from Sigma. Glycopeptides wereenriched on cellulose column or by using ZIC-HILIC spin columns fromEMD. Purified glycopeptides were analyzed by LTQ Orbitrap VelosETD. PEAKSTM Studio Suite was used for spectral preprocessing andprotein identification. GlycoMaster reported 161 identified HCD-ETDspectrum pairs <strong>of</strong> glycopeptides. 95 <strong>of</strong> 161 were manually validated. 68glycopeptides were reported by GlycoMaster, and 40 glycopeptideswere validated.191 Development <strong>of</strong> an AutomatedMethod for Antibody Purificationand AnalysisG. Gendeh, W. Decrop, R. SwartDionex Corporation, Sunnyvale, CA, United StatesThe screening and analysis <strong>of</strong> monoclonal antibodies can be anextremely time consuming task, especially as the many <strong>of</strong> the workflowsused today require many manual steps. This situation is fully remediedby the technology <strong>of</strong>fered by the MAb Analysis platform from Dionex- a single platform can screen a large number <strong>of</strong> MAbs and, in a secondstep, provide detailed analytical information, including charge variantanalysis and aggregate assessment. This unique technology allowsdrug discovery laboratories to develop MAb therapeutics much morequickly than before, and bring these important new therapeutics tomarket in a shorter time frame.192 Fast QC <strong>of</strong> Intact MonoclonalAntibodies Using MALDI-Top-DownSequencingA. Resemann, R. Paape, L. Vorwerg, D. SuckauBruker Daltonics, Bremen, GermanyAntibodies are playing an important role in drug development in thelast years. The function <strong>of</strong> therapeutic monoclonal antibodies (mAbs) isdirectly depending on their structure including terminal modificationslike C-terminal lysine excision and N-terminal pyroglutamylation <strong>of</strong>the heavy chain. Here, we describe a method for very fast and simplevalidation <strong>of</strong> the terminal sequences <strong>of</strong> heavy and light chain <strong>of</strong> intactmonoclonal antibodies using MALDI-Top-Down-Sequencing (MALDI-TDS) using in-source decay (ISD). Intact mAb (IgG) in a concentration<strong>of</strong> 1 mg to 5 mg/ml was directly mixed with matrix solution without priorreduction and alkylation or separation <strong>of</strong> the different chains. We used1,5-diaminonaphtalene (DAN) as matrix because <strong>of</strong> its reductive andISD enhancing properties. The samples were mixed with matrix solutionand dried at ambient air on the MALDI sample plate. In a secondexperiment, the same samples were prepared using sDHB (super DHB),which is known to be a good ISD matrix but without reduction capacity.The samples in sDHB didn’t generate any ISD fragmentation due to theintact disulfide crosslinks in IgG. In DAN, the same samples generatedrich ISD spectra containing fragments from both the heavy and the lightchain <strong>of</strong> the antibodies. The ISD spectra permitted reading throughthe cysteine residues in the sequences implicating the disulfide bridgeswere reduced by DAN. Up to 60 residues <strong>of</strong> the different chains <strong>of</strong>various mAbs were matched and validated, respectively. A dedicateds<strong>of</strong>tware tool allowed a very fast interpretation <strong>of</strong> the spectra. Overallthe method takes only a few minutes from sample preparation,spectrum acquisition and processing to the result in form <strong>of</strong> sequenceannotations in the ISD spectra.**193 Developing a Redox-Sensitive RedFluorescent Protein BiosensorI. Magpiong 1 , N. Koon 2 , S.M. Yei 2 , A.J. Risenmay 2 ,K. Kallio 2 , S.J. Remington 21Mount Holyoke College, South Hadley, MA,United States; 2 University <strong>of</strong> Oregon, Portland, OR,United StatesRedox environments are <strong>of</strong> particular interest, especially in themitochondria with its highly reducing environment and its role as thecentral processing unit <strong>of</strong> apoptosis. Monitoring <strong>of</strong> mitochondrial redoxenvironments is crucial to the study <strong>of</strong> apoptotic disorders. Reporting<strong>of</strong> the thiol/disulfide status in live cells was made possible with thedevelopment <strong>of</strong> redox-sensitive green fluorescent protein (roGFP). Weaim to develop a red version redox-sensitive fluorescent protein (roRFP).Expanding the array <strong>of</strong> redox-sensitive proteins with a red version willenable simultaneous visualization <strong>of</strong> multiple reducing intracellularcompartments. mKeima is a monomeric red fluorescent protein thatabsorbs light maximally at 440nm and emits red light at 620nm. Thislarge Stokes shift is dramatically decreased in acidic environments. Byfollowing protocol similar to that used in the development <strong>of</strong> roGFP,surface residues at key positions were changed to cysteines andrandom mutagenesis was performed on varying excitation species <strong>of</strong>mKeima. Mutants were screened and a ratiometric variant <strong>of</strong> mKeimawas identified (roRFP2) which exhibits changes in its spectral propertiesas a result <strong>of</strong> changes in the thiol/disulfide equilibrium. Preliminaryfluorescence spectroscopy measurements <strong>of</strong> roRFP2 indicate a highlyreducing redox potential <strong>of</strong> -330mV indicating it may be a usefulprobe in reducing subcellular compartments such as mitochondria orin the cytoplasm. By employing vector recombination <strong>of</strong> shuttle vectorPYX142, we successfully targeted roRFP2 in vivo to the mitochondriaand cytoplasm <strong>of</strong> Saccharomyces cerevisiae. Expression <strong>of</strong> roRFP2 wasvisualized using fluorescence microscopy. Thus, through mutagenesisand residue substitution we successfully created a red version redoxsensitivebiosensor that tested effectively as a ratiometric indicatorand expressed in the mitochondria and cytoplasm <strong>of</strong> S. cerevisiae.Moreover, the redox potential <strong>of</strong> roRFP2 is significantly more negativethan the widely used roGFPs.Poster Abstracts<strong>ABRF</strong> <strong>2011</strong> — Technologies to Enable Personalized Medicine • 85
- Page 7 and 8:
Meeting SponsorsThe Association of
- Page 9 and 10:
Registration ServicesRegistration S
- Page 12 and 13:
Presenter InformationPresenter Info
- Page 14 and 15:
AwardsABRF Annual Award for Outstan
- Page 16 and 17:
ABRF Robert A. Welch Outstanding Re
- Page 18 and 19:
Program-at-a-GlanceProgram-at-a-Gla
- Page 20 and 21:
Sunday, February 20 (Continued)(S1-
- Page 22 and 23:
Sunday, February 20 (Continued)(W3-
- Page 24 and 25:
Monday, February 21 (Continued)12:0
- Page 26 and 27:
Tuesday, February 22 (Continued)9:0
- Page 28 and 29:
Tuesday, February 22 (Continued)(W1
- Page 30 and 31:
Satellite Educational Workshop Spon
- Page 32 and 33:
SW2: An Introduction to Metabolomic
- Page 34 and 35:
SW4: Lean Management in Core Facili
- Page 36 and 37: Plenary Session AbstractsPlenary Se
- Page 38 and 39: Scientific Session AbstractsScienti
- Page 40 and 41: Scientific SessionAbstractsstatisti
- Page 42 and 43: Scientific SessionAbstracts(S5) Hig
- Page 44 and 45: Scientific SessionAbstracts(S7-2) S
- Page 46 and 47: Workshop Session AbstractsWorkshop
- Page 48 and 49: Workshop SessionAbstractscase incor
- Page 50 and 51: Workshop SessionAbstracts(W7) Cellu
- Page 52 and 53: Workshop SessionAbstractsresolution
- Page 54 and 55: (W14-3) Galaxy Next Generation Sequ
- Page 56 and 57: Research Group Presentation Abstrac
- Page 58 and 59: Research GroupPresentation Abstract
- Page 60 and 61: Research GroupPresentation Abstract
- Page 62 and 63: Poster Session Abstracts**ABRF Post
- Page 64 and 65: Poster Abstractsglobal gene express
- Page 66 and 67: Poster Abstractsdiscussions of cont
- Page 68 and 69: Poster Abstractspossible applicatio
- Page 70 and 71: Poster Abstracts129 Bravo Automated
- Page 73 and 74: distribution. Additionally, we show
- Page 75 and 76: Illumina Genome Analyzer. PicoPlex
- Page 77 and 78: uniformity, reproducibility of enri
- Page 79 and 80: kits for Tempus TM and PAXgene® st
- Page 81 and 82: 165 Benchmarking miRNA ExpressionLe
- Page 83 and 84: Phoenix crystallography robot and a
- Page 85: Laboratory is located next door and
- Page 89 and 90: **197 Multi-Functional Superparamag
- Page 91 and 92: pattern of N-linked glycans in form
- Page 93 and 94: advantage of using two separate 15
- Page 95 and 96: allowed absolute quantitation. Comp
- Page 97 and 98: levels between the animal groups. A
- Page 99 and 100: MuDPIT, and off-gel electrophoresis
- Page 101 and 102: 237 Multi-Site Assessment of Proteo
- Page 103 and 104: with good limits of quantification
- Page 105 and 106: 249 Rapid Monoclonal Antibody Glyca
- Page 107 and 108: OOng, J. - 117PPatel, S. - 169Peake
- Page 109 and 110: AnaSpec, Eurogentec Group Booth 417
- Page 111 and 112: FASEB MARC Program Booth 4169650 Ro
- Page 113 and 114: IntegenX, Inc. Booth 2015720 Stoner
- Page 115 and 116: Nonlinear Dynamics Booth 1052530 Me
- Page 117 and 118: Roche Applied Science Booth 5009115
- Page 119 and 120: Exhibit Hall FloorplanGrand Oaks Ba
- Page 121 and 122: Exhibitor List in Booth OrderExhibi
- Page 123 and 124: This workshop will present ways to
- Page 125 and 126: Grand Oaks Ballroom,Rooms P&Q, Leve
- Page 127 and 128: NotesNotesABRF 2011 — Technologie
- Page 129 and 130: Tuesday, February 22 — 12:00 pm -
- Page 131 and 132: MARCH 16-20, 2012 • DISNEY’S CO